What is the CJC-1295 + Ipamorelin + IGF-1 LR3 stack?

This is an advanced 3-peptide stack that targets the GH/IGF-1 axis from both ends. CJC-1295 (no DAC) and Ipamorelin stimulate your pituitary to release natural growth hormone (upstream signaling), while IGF-1 LR3 directly activates IGF-1 receptors in muscle and other tissues (downstream signaling). The result is amplified anabolic signaling beyond what either approach achieves alone.

Is this stack suitable for beginners?

No. This is an advanced stack. IGF-1 LR3 is a potent growth factor with risks including hypoglycemia and theoretical concerns about cell proliferation. Beginners should start with the CJC-1295 + Ipamorelin 2-peptide stack first. Only consider adding IGF-1 LR3 after gaining experience with GH secretagogues and understanding how your body responds.

Why not just use IGF-1 LR3 alone instead of adding CJC-1295 and Ipamorelin?

IGF-1 LR3 alone only activates downstream IGF-1 receptors. It does not stimulate your pituitary to release growth hormone, meaning you miss the broader benefits of elevated GH including improved sleep, fat metabolism, and tissue repair mediated through GH-specific pathways. CJC-1295 and Ipamorelin provide the upstream GH pulse, which also triggers your body's own IGF-1 production in the liver. The combination covers the entire axis.

Can I inject CJC-1295/Ipamorelin and IGF-1 LR3 at the same time?

No. They should be separated by at least 6–12 hours. CJC-1295 and Ipamorelin are injected before bed on an empty stomach to amplify the natural nighttime GH pulse. IGF-1 LR3 is injected post-workout or in the morning with food. Injecting them simultaneously can blunt the GH secretagogue effect and does not optimize either pathway.

What are the signs of IGF-1 LR3 hypoglycemia?

Symptoms include shakiness, sweating, dizziness, confusion, rapid heartbeat, irritability, and hunger. IGF-1 LR3 drives glucose into cells similarly to insulin. Always inject with or shortly after a carbohydrate-containing meal, keep fast-acting carbs nearby (juice, glucose tablets), and start at the lowest effective dose (20 mcg). Never inject IGF-1 LR3 in a fasted state.

How long can I run IGF-1 LR3?

IGF-1 LR3 should be limited to 4–6 weeks per cycle. Extended use leads to IGF-1 receptor desensitization, diminishing returns, and increased risk of side effects. After a 4–6 week IGF-1 LR3 cycle, take at least 4 weeks off before repeating. CJC-1295 and Ipamorelin can continue during the IGF-1 LR3 off-period.

Do I need to monitor blood work on this stack?

Yes. At minimum, check fasting blood glucose, IGF-1 serum levels, and a comprehensive metabolic panel before starting and midway through the cycle. IGF-1 LR3 can significantly elevate circulating IGF-1 and affect glucose metabolism. Monitoring is not optional with this stack — it is a safety requirement.

Can I add a fourth peptide like Tesamorelin to this stack?

Some advanced users add Tesamorelin (a GHRH analog) to create a 4-peptide GH stack. However, adding more compounds increases complexity and risk without proportional benefit for most users. The 3-peptide stack already covers both upstream GH release and downstream IGF-1 activation. Only consider a 4-peptide approach under medical supervision with regular blood work.

Will this stack cause organ growth?

At therapeutic doses and short cycle lengths (4–6 weeks for IGF-1 LR3), organ growth is not a realistic concern. Organ growth (visceromegaly) is associated with chronic supraphysiological GH and IGF-1 levels over months to years, typically seen with high-dose exogenous HGH abuse. Following recommended doses and cycle lengths keeps this risk negligible.

Is this stack banned in sports?

Yes. All three peptides are prohibited by the World Anti-Doping Agency (WADA). CJC-1295 and Ipamorelin fall under GH-releasing peptides, and IGF-1 LR3 falls under peptide hormones and growth factors. Athletes subject to anti-doping testing must not use this stack.

What is the difference between CJC-1295 with DAC and without DAC?

CJC-1295 without DAC (also called Mod GRF 1-29) has a short half-life of about 30 minutes, creating a sharp GH pulse similar to natural secretion. CJC-1295 with DAC has a half-life of about 8 days, creating a sustained but blunted GH elevation. For this stack, CJC-1295 without DAC (no DAC) is strongly preferred because it produces a more physiological GH pulse pattern and allows precise timing around sleep.

Can women use this stack?

Women can use CJC-1295 and Ipamorelin at standard doses. However, IGF-1 LR3 should be approached with extra caution and at the lower end of the dosing range (20–30 mcg). Women may be more sensitive to the glucose-lowering effects of IGF-1 LR3. Starting conservatively and monitoring blood glucose carefully is essential.

CJC-1295 + Ipamorelin + IGF-1 LR3 Stack Guide

Advanced 3-peptide stack targeting the GH/IGF-1 axis from both ends — GH secretagogues for upstream pituitary stimulation plus direct IGF-1 receptor activation for maximum anabolic signaling, muscle growth, and recovery.

Compiled by PeptideWiki Editorial Team

Stack Overview

Advanced Stack Warning: This is NOT a beginner stack. IGF-1 LR3 is a potent growth factor that carries real risks including hypoglycemia and theoretical concerns about cell proliferation. You should have prior experience with GH secretagogues (CJC-1295 + Ipamorelin alone) before adding IGF-1 LR3. Blood glucose and IGF-1 level monitoring is required. Consult a healthcare provider before use.

The CJC-1295 + Ipamorelin + IGF-1 LR3 stack is an advanced 3-peptide protocol that targets the GH/IGF-1 axis from both upstream and downstream. CJC-1295 and Ipamorelin stimulate the pituitary gland to release natural growth hormone, while IGF-1 LR3 directly activates IGF-1 receptors in muscle and other tissues. Together, they produce amplified anabolic signaling beyond what either approach achieves alone.

Key Characteristics:

3-peptide stack — CJC-1295 (no DAC / Mod GRF 1-29) + Ipamorelin + IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1)
Primary goal — muscle growth, enhanced recovery, body recomposition, and anabolic signaling optimization
Dual-axis mechanism — CJC-1295/Ipamorelin stimulate natural GH release (upstream); IGF-1 LR3 directly activates IGF-1 receptors (downstream) — covering the entire GH/IGF-1 axis
Experience level — advanced users only — requires prior experience with GH secretagogues and regular blood work monitoring
Typical cycle — CJC-1295/Ipamorelin 8–12 weeks; IGF-1 LR3 4–6 weeks max (staggered)
Administration — subcutaneous injection for all three peptides; different timing for secretagogues vs. IGF-1 LR3

Use our Peptide Dosage Calculator to calculate exact doses for all three peptides based on your vial sizes and reconstitution volumes.

Important: None of the peptides in this stack are FDA-approved for human use. All are classified as research peptides. Dosing information in this guide is derived from animal studies, clinical research, and community protocols — not from controlled human clinical trials of this specific combination. Consult a healthcare provider before using any research peptide.

Why This Stack Works

This stack is effective because it targets the GH/IGF-1 axis from both ends simultaneously. Rather than relying solely on stimulating GH release or solely on exogenous IGF-1, it combines both approaches for a synergistic anabolic effect that neither achieves alone.

CJC-1295 (no DAC): The GH-Releasing Hormone Analog

GHRH mimetic: binds to GHRH receptors on the pituitary, amplifying the natural growth hormone releasing hormone signal
GH pulse amplification: increases the amplitude of GH pulses rather than creating a constant elevation, preserving the natural pulsatile pattern
Short half-life (~30 min): produces a sharp, physiological GH pulse ideal for bedtime injection
Synergy with Ipamorelin: GHRH and ghrelin pathways are additive — combining both produces a larger GH pulse than either alone

Ipamorelin: The Selective GH Secretagogue

Ghrelin mimetic: binds to the growth hormone secretagogue receptor (GHS-R) on the pituitary, triggering GH release through the ghrelin pathway
Selective: unlike GHRP-6 or Hexarelin, Ipamorelin does not significantly increase cortisol, prolactin, or appetite at standard doses
Complementary to CJC-1295: activates a different receptor pathway (ghrelin vs. GHRH), producing an additive GH pulse when combined
Well-tolerated: one of the mildest GH secretagogues with minimal side effects

IGF-1 LR3: The Direct Growth Factor

Direct IGF-1 receptor activation: bypasses the pituitary and liver entirely, directly binding to and activating IGF-1 receptors in muscle and other tissues
Extended half-life: the LR3 modification reduces binding to IGF-binding proteins, extending the half-life to approximately 20–30 hours (vs. ~15 minutes for native IGF-1)
Potent anabolic: promotes muscle cell hyperplasia (new cell formation) in addition to hypertrophy (cell enlargement) — a mechanism not shared by GH alone
Glucose partitioning: drives glucose and amino acids into muscle cells, enhancing nutrient uptake and recovery

The Synergy

CJC-1295 and Ipamorelin trigger a large natural GH pulse from the pituitary. This GH travels to the liver and stimulates endogenous IGF-1 production. Meanwhile, IGF-1 LR3 adds direct, exogenous IGF-1 receptor activation on top of the body's own response. The result: elevated GH for its direct benefits (fat metabolism, sleep quality, tissue repair) plus amplified IGF-1 signaling for its anabolic effects (muscle protein synthesis, hyperplasia, nutrient partitioning). This dual-axis approach produces a greater total anabolic effect than either upstream or downstream stimulation alone.

Evidence note: CJC-1295 and Ipamorelin have human clinical data supporting their GH-releasing effects individually. IGF-1 LR3's effects are well-characterized in cell and animal models. The synergistic benefit of this specific 3-peptide combination is primarily supported by mechanistic reasoning and community protocols rather than controlled human trials of the combination.

Individual Peptide Breakdown

Each peptide in this stack has a dedicated dosage guide with complete individual protocols. Here is a summary of each peptide's role in this stack.

CJC-1295 (no DAC / Mod GRF 1-29)

Type: Synthetic GHRH analog (modified tetrasubstituted peptide)
Origin: Modified fragment of growth hormone releasing hormone (GHRH)
Role in stack: Amplifies natural GH pulses via GHRH receptor activation
Route: Subcutaneous injection
Frequency: Once daily (before bed)

Full CJC-1295 Dosage Guide →

Ipamorelin

Type: Selective growth hormone secretagogue (pentapeptide)
Origin: Synthetic ghrelin mimetic designed for selective GH release
Role in stack: Triggers GH release via ghrelin receptor (GHS-R), additive with CJC-1295
Route: Subcutaneous injection
Frequency: Once daily (before bed, with CJC-1295)

Full Ipamorelin Dosage Guide →

IGF-1 LR3 (Long R3 IGF-1)

Type: Modified insulin-like growth factor (83 amino acids)
Origin: Recombinant analog of human IGF-1 with extended half-life
Role in stack: Direct IGF-1 receptor activation for anabolic signaling and nutrient partitioning
Route: Subcutaneous injection
Frequency: Once daily (post-workout or morning)

Full IGF-1 LR3 Dosage Guide →

Dosing Protocol

This stack uses two separate injection windows: a bedtime session for the GH secretagogues and a morning/post-workout session for IGF-1 LR3. Timing separation is critical for optimal results.

Standard Protocol

Compound	Dose	Timing	Route	Notes
CJC-1295	100 mcg	Before bed (fasted)	SubQ (abdomen)	At least 2 hours after last meal; inject with Ipamorelin
Ipamorelin	100–200 mcg	Before bed (fasted)	SubQ (abdomen)	Same injection session as CJC-1295; separate syringes
IGF-1 LR3	20–50 mcg	Post-workout or morning	SubQ (abdomen or near target muscle)	With or after a carbohydrate-containing meal; start at 20 mcg

Conservative Protocol (Starting Doses)

Compound	Dose	Timing	Route	Notes
CJC-1295	100 mcg	Before bed (fasted)	SubQ	Standard dose; no need to titrate
Ipamorelin	100 mcg	Before bed (fasted)	SubQ	Lower end of range; can increase to 200 mcg if well-tolerated
IGF-1 LR3	20 mcg	Post-workout or morning	SubQ	Start here; increase by 10 mcg/week only if well-tolerated

IGF-1 LR3 dose titration: Always start IGF-1 LR3 at 20 mcg and assess tolerance for at least one week before increasing. Monitor for signs of hypoglycemia (shakiness, sweating, dizziness, confusion). Increase by 10 mcg per week up to a maximum of 50 mcg only if tolerated well. Not everyone needs or should reach the upper dose range.

Calculate Your Doses

All three peptides are supplied as lyophilized powder and need reconstitution with bacteriostatic water. The dose you draw depends on the concentration after reconstitution.

CJC-1295 (no DAC) — 2 mg Vial

Vial size: 2 mg (2,000 mcg)
Bacteriostatic water: 2 mL
Concentration: 2,000 ÷ 2 = 1,000 mcg/mL
100 mcg dose = 0.1 mL = 10 units on insulin syringe
Doses per vial: 20 doses

Ipamorelin — 2 mg Vial

Vial size: 2 mg (2,000 mcg)
Bacteriostatic water: 2 mL
Concentration: 2,000 ÷ 2 = 1,000 mcg/mL
200 mcg dose = 0.2 mL = 20 units on insulin syringe
Doses per vial: 10 doses (at 200 mcg)

IGF-1 LR3 — 1 mg Vial

Vial size: 1 mg (1,000 mcg)
Bacteriostatic water: 1 mL
Concentration: 1,000 ÷ 1 = 1,000 mcg/mL
50 mcg dose = 0.05 mL = 5 units on insulin syringe
Doses per vial: 20 doses (at 50 mcg)

Skip the Math — Use Our Calculator

Enter your vial size, water volume, and desired dose for each peptide — get instant calculations with zero manual math.

Reconstitution Guide

All three peptides follow the same reconstitution process. Reconstitute each vial separately with bacteriostatic water.

Peptide	Vial Size	Bac Water	Concentration	Standard Dose Draw
CJC-1295 (no DAC)	2 mg	2 mL	1,000 mcg/mL	10 units (0.1 mL) for 100 mcg
Ipamorelin	2 mg	2 mL	1,000 mcg/mL	20 units (0.2 mL) for 200 mcg
IGF-1 LR3	1 mg	1 mL	1,000 mcg/mL	5 units (0.05 mL) for 50 mcg

Wash Hands & Prepare Workspace

Wash hands thoroughly. Lay out supplies: peptide vials, bacteriostatic water, insulin syringes, and alcohol swabs on a clean surface.

Swab All Vial Stoppers

Remove plastic caps and swab the rubber stoppers of each peptide vial and the bacteriostatic water vial with alcohol pads. Let air-dry for 10–15 seconds.

Add Water to Peptide Vial

Draw the appropriate volume of bacteriostatic water. Insert needle into peptide vial and direct the stream down the inside glass wall — never squirt directly onto the powder. Release slowly.

Dissolve Gently

Let the vial sit for 1–2 minutes, then gently swirl or roll between palms until fully dissolved. Solution should be clear and colorless. Never shake.

Label & Refrigerate

Write the reconstitution date, peptide name, and concentration on each vial. Store refrigerated at 2–8°C. Use within 28–30 days.

IGF-1 LR3 handling: IGF-1 LR3 is more fragile than GH secretagogues. Be especially gentle during reconstitution — never shake. Some users add 0.1 mL of acetic acid (0.6%) to the vial before bacteriostatic water to improve solubility, but plain bacteriostatic water works for most formulations.

For a detailed visual walkthrough, see our Reconstitution Guide.

Timing & Daily Schedule

Timing separation is the most important aspect of this stack. The GH secretagogues and IGF-1 LR3 must be injected at different times of day for different reasons.

Training Day Schedule

Time	Action	Details
Morning / Post-Workout	IGF-1 LR3 injection	20–50 mcg SubQ with or after a carbohydrate-containing meal
Throughout Day	Normal meals and training	Ensure adequate protein and carbohydrate intake
2+ Hours After Last Meal	CJC-1295 + Ipamorelin injection	100 mcg CJC-1295 + 100–200 mcg Ipamorelin SubQ, fasted
Immediately After	Sleep	Do not eat after the bedtime injection — go to sleep to maximize the GH pulse

Rest Day Schedule

Time	Action	Details
Morning (with breakfast)	IGF-1 LR3 injection	20–50 mcg SubQ with or after breakfast
2+ Hours After Last Meal	CJC-1295 + Ipamorelin injection	100 mcg CJC-1295 + 100–200 mcg Ipamorelin SubQ, fasted
Immediately After	Sleep	Maximize the natural nighttime GH pulse

Critical Timing Notes

CJC-1295 + Ipamorelin: Must be injected in a fasted state (at least 2 hours after food). Carbohydrates and fats blunt the GH response. Inject before bed and go directly to sleep.
IGF-1 LR3: Must be injected with or after food (especially carbohydrates) to prevent hypoglycemia. Post-workout is ideal because muscles are primed for nutrient uptake. On rest days, inject with breakfast.
Separation: Space IGF-1 LR3 and CJC-1295/Ipamorelin injections at least 6–12 hours apart. They have opposite food requirements (fed vs. fasted) and different mechanisms that are best activated separately.
CJC-1295 and Ipamorelin together: These two can and should be injected in the same session using separate syringes. No waiting period between them.

Never inject IGF-1 LR3 before bed in a fasted state. This creates a risk of nocturnal hypoglycemia, which can be dangerous. IGF-1 LR3 belongs in the morning or post-workout window with food. The bedtime window is exclusively for CJC-1295 and Ipamorelin.

Cycling & Duration

The key to cycling this stack is that CJC-1295/Ipamorelin and IGF-1 LR3 have different cycle lengths. The GH secretagogues can run longer, while IGF-1 LR3 must be cycled more aggressively to prevent receptor desensitization.

Phase	Duration	CJC-1295 + Ipamorelin	IGF-1 LR3
Full Stack	Weeks 1–4 (or 1–6)	100 mcg + 100–200 mcg nightly	20–50 mcg daily (AM/post-workout)
Secretagogues Only	Weeks 5–12 (or 7–12)	100 mcg + 100–200 mcg nightly	Off — receptor resensitization
Break	2–4 weeks off	None	None
Repeat (if needed)	8–12 weeks	Resume full protocol	Resume at starting dose (20 mcg)

Why Stagger the Cycles?

IGF-1 receptor desensitization: IGF-1 LR3 causes downregulation of IGF-1 receptors with prolonged use. Limiting it to 4–6 weeks preserves receptor sensitivity and effectiveness.
CJC-1295/Ipamorelin tolerance: GH secretagogues have a much lower desensitization risk and can be run for 8–12 weeks. They continue providing GH and endogenous IGF-1 benefits during the IGF-1 LR3 off-period.
Safety margin: Rotating IGF-1 LR3 on and off reduces cumulative exposure to a potent growth factor while maintaining baseline GH support from the secretagogues.

Alternative: Shorter Cycle

Some users prefer a shorter approach: 4 weeks of the full stack followed by 4 weeks of CJC-1295/Ipamorelin only, then 2–4 weeks fully off. This reduces total IGF-1 LR3 exposure and is appropriate for users who are more conservative or new to IGF-1 LR3.

Safety, Side Effects & Contraindications

This stack carries higher risk than GH secretagogues alone. IGF-1 LR3 is a potent growth factor with real risks including hypoglycemia and theoretical concerns about promoting cell proliferation. Blood work monitoring is not optional. This section must be read and understood before starting this protocol.

CJC-1295/Ipamorelin Side Effects (Generally Mild)

Water retention and mild bloating — common in the first 1–2 weeks, usually resolves
Injection site redness or irritation — the most common local reaction
Tingling or numbness in hands/feet — a sign of elevated GH, typically transient
Increased hunger (more common with higher Ipamorelin doses)
Vivid dreams or improved sleep depth — generally considered a positive effect
Mild headache — usually resolves within the first week

IGF-1 LR3 Side Effects (Require Monitoring)

Hypoglycemia: the primary acute risk. IGF-1 LR3 drives glucose into cells similarly to insulin. Symptoms: shakiness, sweating, confusion, dizziness, rapid heartbeat. Always inject with food and keep fast-acting carbs available.
Jaw pain or joint aches: may indicate excessive growth factor stimulation. Reduce dose if this occurs.
Localized swelling or pump: some users report increased muscle fullness or pump in injected areas. Generally benign.
Headache and fatigue: can occur especially during the first few days of use.
Gut distension: at high doses over extended periods, IGF-1 promotes growth of intestinal tissue. This is avoided by staying within recommended doses and cycle lengths.

Contraindications

Active cancer or history of cancer: IGF-1 promotes cell proliferation and angiogenesis. This is a serious contraindication for IGF-1 LR3 specifically, and applies to the entire stack.
Diabetes or impaired glucose tolerance: IGF-1 LR3's glucose-lowering effect can be dangerous for individuals with existing blood sugar regulation issues.
Pregnancy and breastfeeding: No safety data exists for any of these peptides during pregnancy or nursing. Avoid entirely.
Under 25 years of age: Growth plates may still be open, and manipulating the GH/IGF-1 axis during development is inadvisable.
Active pituitary conditions: CJC-1295 and Ipamorelin act on the pituitary. Existing pituitary tumors or conditions are a contraindication.

Required Blood Work

Fasting blood glucose — check before starting and every 2 weeks during IGF-1 LR3 use
IGF-1 serum levels — check before starting and at week 4 to ensure levels are within a reasonable range
Comprehensive metabolic panel (CMP) — baseline and midway through the cycle for liver and kidney function
HbA1c — if running multiple cycles, check every 3 months to monitor long-term glucose control

Regulatory status: None of the peptides in this stack are FDA-approved for human use. All are classified as research peptides. All three are prohibited by WADA for competitive athletes. Regulations vary by jurisdiction — verify your local laws before purchasing.

Common Stack Mistakes

Avoid these common errors to get the most out of your CJC-1295 + Ipamorelin + IGF-1 LR3 protocol safely:

Injecting IGF-1 LR3 at the same time as CJC-1295/Ipamorelin

CJC-1295 and Ipamorelin need to be taken fasted before bed to amplify the natural GH pulse. IGF-1 LR3 should be taken post-workout or in the morning with food. Injecting them together blunts the GH secretagogue effect and fails to optimize either mechanism. Space them at least 6–12 hours apart.

Running IGF-1 LR3 for longer than 6 weeks

IGF-1 LR3 causes receptor desensitization with extended use. After 4–6 weeks, IGF-1 receptors downregulate and you get diminishing returns with increasing risk. Limit IGF-1 LR3 to 4–6 weeks, then take at least 4 weeks off. CJC-1295/Ipamorelin can continue during the off-period.

Injecting IGF-1 LR3 while fasted

IGF-1 LR3 drives glucose into cells similarly to insulin. Injecting in a fasted state significantly increases hypoglycemia risk — symptoms include shakiness, confusion, and dizziness. Always inject IGF-1 LR3 with or shortly after a meal containing carbohydrates.

Starting at high IGF-1 LR3 doses

Jumping straight to 50 mcg or higher without assessing tolerance is reckless. Start at 20 mcg and increase by 10 mcg per week only if well-tolerated. Individual sensitivity varies substantially. Some users experience hypoglycemia even at moderate doses.

Treating this as a beginner stack

The CJC-1295/Ipamorelin pair is beginner-friendly, but adding IGF-1 LR3 changes the risk profile entirely. IGF-1 LR3 is a potent growth factor with real risks including hypoglycemia, and theoretical concerns about cell proliferation. Start with the 2-peptide GH secretagogue stack first. Only add IGF-1 LR3 after gaining experience.

Not eating enough carbohydrates around IGF-1 LR3 injections

IGF-1 LR3 increases cellular glucose uptake. Without adequate carbohydrate intake around the injection window, blood sugar can drop to symptomatic levels. Plan to consume 30–50g of carbohydrates with or within 30 minutes of your IGF-1 LR3 injection.

Skipping blood work

This stack directly manipulates the GH/IGF-1 axis. Running it without monitoring fasting glucose, IGF-1 serum levels, and a basic metabolic panel is flying blind. Blood work before starting and midway through the cycle is a safety requirement, not a suggestion.

Eating before the CJC-1295/Ipamorelin bedtime injection

Food — especially carbohydrates and fats — blunts the GH response from secretagogues. CJC-1295 and Ipamorelin must be injected at least 2 hours after your last meal. The fasted state is critical for maximizing the nighttime GH pulse.

Frequently Asked Questions

Key Takeaways

This is an advanced 3-peptide stack targeting the GH/IGF-1 axis from both ends — upstream GH release (CJC-1295/Ipamorelin) plus downstream IGF-1 receptor activation (IGF-1 LR3)
CJC-1295 (100 mcg) + Ipamorelin (100–200 mcg) before bed, fasted — to amplify the natural nighttime GH pulse
IGF-1 LR3 (20–50 mcg) post-workout or morning, with food — to directly activate IGF-1 receptors and drive nutrient partitioning
Never inject IGF-1 LR3 and CJC-1295/Ipamorelin at the same time — space them at least 6–12 hours apart
IGF-1 LR3: 4–6 weeks max, then at least 4 weeks off — receptor desensitization occurs with extended use
CJC-1295/Ipamorelin: 8–12 weeks — can continue during the IGF-1 LR3 off-period
Always eat carbohydrates with IGF-1 LR3 injections — hypoglycemia is the primary acute risk
Blood work is required, not optional — monitor fasting glucose, IGF-1 levels, and metabolic panel
Not for beginners — gain experience with CJC-1295 + Ipamorelin alone before adding IGF-1 LR3
None of these peptides are FDA-approved for human use. All are classified as research peptides and banned by WADA.

This article is for educational and informational purposes only. CJC-1295, Ipamorelin, and IGF-1 LR3 are not approved by the FDA for human use and are classified as research peptides. They are not intended to diagnose, treat, cure, or prevent any disease. IGF-1 LR3 carries additional risks including hypoglycemia and theoretical concerns about cell proliferation. Consult a qualified healthcare provider before using any research peptide, especially if you have pre-existing medical conditions, diabetes or impaired glucose tolerance, are taking medications, or are pregnant or nursing. See our Medical Disclaimer.

References

Teichman SL, et al. “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.” J Clin Endocrinol Metab. 2006;91(3):799-805.
Raun K, et al. “Ipamorelin, the first selective growth hormone secretagogue.” Eur J Endocrinol. 1998;139(5):552-561.
Francis GL, et al. “Insulin-like growth factor 1 and insulin-like growth factor 2 in Bovine Colostrum.” Biochem J. 1988;251(1):95-103.
Tomas FM, et al. “Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats.” Biochem J. 1993;292(Pt 3):857-862.
Clemmons DR. “Role of IGF-I in skeletal muscle mass maintenance.” Trends Endocrinol Metab. 2009;20(7):349-356.
Pollak M. “The insulin and insulin-like growth factor receptor family in neoplasia: an update.” Nat Rev Cancer. 2012;12(3):159-169.
Giustina A, Veldhuis JD. “Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human.” Endocr Rev. 1998;19(6):717-797.
Florini JR, et al. “Growth hormone and the insulin-like growth factor system in myogenesis.” Endocr Rev. 1996;17(5):481-517.